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Abstract
The ability to screen compounds in a high-throughput manner is essential in the process of small molecule drug discovery.
Critical to the success of screening strategies is the proper design of the assay, often implying a compromise between ease/
speed and a biologically relevant setting. Leishmaniasis is a major neglected disease with limited therapeutic options. In
order to streamline efforts for the design of productive drug screens against Leishmania, we compared the efficiency of two
screening methods, one targeting the free living and easily cultured promastigote (insect–infective) stage, the other
targeting the clinically relevant but more difficult to culture intra-macrophage amastigote (mammal-infective) stage.
Screening of a 909-member library of bioactive compounds against Leishmania donovani revealed 59 hits in the
promastigote primary screen and 27 in the intracellular amastigote screen, with 26 hits shared by both screens. This
suggested that screening against the promastigote stage, although more suitable for automation, fails to identify all active
compounds and leads to numerous false positive hits. Of particular interest was the identification of one compound specific
to the infective amastigote stage of the parasite. This compound affects intracellular but not axenic parasites, suggesting a
host cell-dependent mechanism of action, opening new avenues for anti-leishmanial chemotherapy.
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Introduction
Leishmaniasis is caused by protozoan parasites of the genus
Leishmania. The disease is endemic in the tropics, subtropics and
the Mediterranean basin. There are three main clinical syndromes
caused by different species of Leishmania. Cutaneous and
muccocutaneous leishmaniasis result in large, painful sores that
can take many months to heal [1]. Visceral leishmaniasis results in
fever, weight loss, and damage to internal organs such as the
spleen and the liver and may be fatal if left untreated [2].
Leishmania parasites are transmitted to mammalian hosts
through the bite of phlebotomine sandflies. The parasites that
develop in the mid-gut of the flies, called promastigotes, are
flagellated and extracellular. Upon injection in the bloodstream of
a mammalian host, promastigotes are rapidly phagocytosed by
macrophages where they differentiate into the amastigote form.
Amastigotes multiply in the macrophage parasitophorous vacuole,
leading to destruction of the host cell and release of free
amastigotes into the bloodstream, where they are capable of
infecting new phagocytic cells [3].
Current treatment for leishmaniasis relies on chemotherapy, as
no efficient vaccine is available. Sodium stibogluconate and
amphotericin B have been the first line treatment; however, they
have significant side effects and unresponsiveness to sodium
stibogluconate has been reported for many years [4–6]. A few new
anti-leishmanial drugs have been recently released (miltefosine,
paromomycin), but they also have drawbacks including cost and
toxicity [7]. In addition, it has been shown in vitro that in some
cases resistance can be easily induced [8].
New therapeutics are therefore urgently needed. Recognition of
this need in recent years has led to partnerships between a number
of foundations, agencies and universities to support the discovery
of anti-parasitic agents, including anti-leishmanials. Lead discov-
ery, one of the bottlenecks in the pipeline for novel anti-
leishmanial drugs, would be facilitated by improved high-
throughput technology allowing for the ability to screen large
number of candidates [9,10]. Several anti-leishmanial high-
throughput screens have been reported [11–13]. Primary screens
often target the parasite promastigote stage because of ease of
culture and manipulation. Indeed, promastigotes from several
Leishmania species are easily maintained as cell suspension in vitro.
However, as the promastigote is the form of the parasite in the
insect vector, it is not the appropriate target for an anti-leishmanial
drug [14]. Culture conditions for axenic amastigotes have been
developed in order to facilitate the study of this stage of the
parasite [15,16]. This has allowed amastigotes to be screened in a
high-throughput manner [17]. However, expression arrays
comparing L. infantum axenic amastigotes and amastigotes isolated
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processes, including metabolism, intracellular transport and
response to oxidative stress [18]. These observations highlight
the importance of the host macrophage in driving the parasite to
specific adaptations. The axenic amastigote model therefore has
limitations as it does not encompass many aspects of intracellular
parasite development [19]. Compounds active against axenic
forms might be unable to reach the intracellular amastigote
because of their inability to cross host cell membranes or maintain
stability under low pH. Other compounds may need to be
metabolized by the macrophage to gain activity. Finally, the
macrophage itself might be directly targeted, thereby leading to
parasite growth inhibition [20].
We have developed a host cell-based screening assay using a
human macrophage cell line infected with L. donovani, one of the
agents of visceral leishmaniasis. This assay format enables
screening of compounds directly against the intracellular stage of
the parasite. This assay was used to screen a library of 909
bioactive compounds consisting largely of FDA approved small
molecules. In order to compare the efficiency of this screening
method with traditional high-throughput screening assays, the
same compound library was screened against free living
promastigotes. A compound leading to sixty percent parasite
growth inhibition at 10 mM was considered a hit in both assays. 59
hits were identified in the promastigote assay of which only 26
were also considered hits in the intracellular amastigote assay.
Only one compound was specifically active against the intracel-
lular amastigote stage. We conclude that the promastigote assay
fails to identify all active compounds and leads to a rate of 56%
false positives.
Materials and Methods
Cell culture
THP-1 cells (human acute monocytic leukemia cell line –
ATCC TIB202) were grown in RPMI supplemented with 10%
Foetal Bovine Serum (FBS) and 50 mM 2-Mercaptoethanol at
37uC in 5% CO2. L. donovani promastigotes [strain 1S, clone 2D
(MHOM/SD/62/1S-cl2D)] were grown at 27uC in RPMI
supplemented with 10% FBS and 10% Brain Heart Tryptose
medium (BHT) [21]. Differentiation of promastigotes into axenic
amastigotes was achieved by dilution of 5610
5 promastigotes in
3 ml of low-pH axenic amastigote media (15 mM KCl; 136 mM
KH2PO4; 10 mM K2HPO4?3H2O; 0.5 mM MgSO4?7H2O;
24 mM NaHCO3; 22 mM glucose; 1 mM glutamine, 16RPMI
1640 vitamin mix, 10 mM folic acid, 100 mM adenosine, 16
RPMI amino acid mix, 5 mg/ml hemin, 50 U/ml of penicillin,
50 mg/ml of streptomycin, 25 mM MES and 20% FBS. The pH
was adjusted to pH 5.66 at 22uC, yielding a final pH of 5.5 at
37uC) [22]. Axenic amastigotes were grown in ventilated flasks at
37uC in 5% CO2.
Compounds
A library of 909 bioactive compounds was donated by Iconix
Biosciences. These compounds were dissolved in DMSO at a stock
concentration of 1 mM. Amphotericin B (Sigma) was used as a
positive control.
Promastigote high-throughput assay
L. donovani promastigotes from an exponentially growing culture
were diluted to 10
6/ml in RPMI containing 10% FBS and 10%
BHT. The diluted culture (99 ml/well) was dispensed in sterile 96-
well flat white opaque assay plates (Greiner Bio-One) using a
WellMate multichannel dispenser (Matrix). 1 ml of 1 mM test
compound dissolved in DMSO was added to the plates for a final
concentration of 10 mM compound and 1% DMSO. Amphoter-
icin B was added as a positive control (final concentration 2 mM,
1% DMSO) and as a negative control, 1 ml DMSO was added
(1% final concentration). Compounds and controls were added to
the assay plate with the robotic dispenser Biomek FXp liquid
handler (Beckman Coulter). Promastigotes were incubated with
the compounds for 72 h at 27uC. The parasites were then lysed by
adding 50 ml of CellTiter-Glo (Promega) and placed on an orbital
shaker for 5 min at room temperature. After lysis, the resulting
ATP-bioluminescence was measured using the Analyst HT plate
reader (Molecular Devices). Percentage inhibition of parasite
growth was calculated for each well as [1-(RLUx-RLU
+)/(RLU
--
RLU
+)]*100 where RLUx, RLU
+ and RLU
- are respectively the
Relative Light Units for each well, positive (amphotericin B) and
negative (DMSO) controls. A screening window coefficient,
denoted Z’ factor, was used to evaluate the performance of the
assay. The Z’ factor, calculated as 1-(3sc++3sc2)/(mc+2mc2)
where sc+, sc2, mc+ and mc2 are respectively the standard
deviation and mean values of positive and negative controls, is
reflective of the assay signal dynamic range and the data variation
associated with signal measurement [23]. For GI50 determinations
(half maximal inhibitory concentration), compounds were serially
diluted 3-fold in DMSO, with final assay concentrations ranging
from 50 mM to 0.02 mM (1% final concentration of DMSO). GI50
curve fitting was carried out using GraphPad Prism 4 Software
(GraphPad Software Inc., San Diego, CA).
Intracellular amastigote high-throughput assay
Sterile, black, 96-well, clear bottom plates (Greiner Bio-One)
were seeded with exponentially growing THP-1 (5610
5cells/ml).
THP-1 were treated with 0.1 mM phorbol myristate acetate (PMA,
Sigma) at 37uC for 48 h to achieve differentiation into adherent,
non-dividing macrophages. Maturation of THP-1 cells towards
monocyte-macrophage like cells is essential to avoid parasitized
cells being overgrown by replicating cells. After activation by
PMA, cells were washed and incubated with complete RPMI
medium containing stationary phase L. donovani promastigotes at a
macrophage/promastigote ratio of 1/15. After 4 h incubation at
37uC, non-internalized promastigotes were removed by 2–3
successive washes with RPMI containing 5% FBS and 5% horse
Author Summary
Leishmaniasis, a disease caused by protozoan parasites of
the genus Leishmania, is a poverty-related disease threat-
ening 350 million people throughout the world. Drugs
currently available to treat this disease are toxic to the
patient and drug-resistant parasites are emerging. New
therapeutics are therefore needed. Fortunately, interest in
confronting the treatment challenges has grown and new
technology has led to an increase in high-throughput
screens conducted against Leishmania. In order to gain
insight into the most efficient screening strategy, we
compared two methods, one targeting the easily cultured
insect-infective promastigote stage of the parasite, and the
other, targeting the clinically relevant but more difficult to
culture intracellular amastigote stage. We show that while a
screen against promastigotes is amenable to automation, it
fails to recognize all active compounds. These compounds
revealed only by an intracellular assay might act on host cell
pathways important for parasite development. Targeting
such pathways is an emerging strategy in drug discovery
against infectious diseases.
Screen against Leishmania Intracellular Amastigote
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tericin B) or negative control (1% DMSO) were then added to the
cultures using a Biomek FXp liquid handler (Beckman Coulter).
Cultures were incubated at 37uC for 72 h. Cells were then washed
with phosphate-buffered saline (PBS), fixed for 30 minutes with
4% formaldehyde, rinsed again with PBS, stained for 2 h with
49,69-diamidino-2-phenylindole (DAPI 300 nM) and finally
washed with PBS. For GI50 determination, compounds were
serially diluted 3-fold in DMSO, with final assay concentrations
ranging from 50 mM to 0.02 mM (1% final concentration of
DMSO). Images were acquired with an INCell Analyzer 1000
automated epi-fluorescent microscope (G.E. Healthcare). The
excitation and emission filters used to detect DAPI were 350/
50 nm and 460/40 nm respectively. Eight image fields were
acquired per well with a 20X objective. The proprietary INCell
Developer Toolbox 1.7 software was used for image analysis.
Segmentation parameters were set to identify host nuclei with a
minimum area of 250 mm
2 and parasite kinetoplast with an
average area of 1 mm
2. The intensity of parasite nucleus was too
low to be detected with a 20X objective. A border, representing
the boundary of the cell, was drawn around the nucleus (total area
between 700 and 2000 mm
2). Only parasites found within this area
were included in the calculation to eliminate extracellular
parasites. False positive parasite detection in the nucleus was also
excluded from the calculation. Host cell nuclei and parasite
kinetoplasts were counted and the ratio of parasites DNA to host
nuclei was selected as the measurement output. Percentage
inhibition of parasite growth was calculated as [1-(P/hcx-P/hc
+)/
(P/hc
2-P/hc
+)]*100 where P/hcx, P/hc
+ and P/hc
2 are parasite
per host cell ratio for every well, positive control (amphotericin B)
and negative control (DMSO) respectively. Calculation of Z’ factor
and GI50 curve fitting were carried out as described above.
Dose response study against axenic amastigotes
L. donovani axenic amastigotes (5610
5 cells/ml in axenic
amastigote media) were dispensed in sterile 96-well flat white
opaque assay plates (Greiner Bio-One) using a WellMate
multichannel dispenser (Matrix). Compounds were serially diluted
3-fold in DMSO, with final assay concentrations ranging from
50 mM to 0.02 mM (1% final concentration of DMSO). 1%
DMSO and amphotericin B (2 mM, 1% DMSO final concentra-
tion) were added as negative and positive controls respectively.
Axenic amastigotes were incubated with the compounds for 72 h
at 37uC with 5% CO2. Parasite viability was then measured using
CellTiter-Glo as described above. Calculation of Z’ factor,
percentage of parasite growth inhibition and GI50 curve fitting
were carried out as described above.
Results
Development of an image-based high-throughput assay
for drug screening against intracellular L. donovani
We developed a 96-well plate, cell-based assay simple to
manipulate and reproducible, enabling screening of a high
number of compounds against intra-macrophage L. donovani.
The human leukemia monocyte cell line THP-1 has been
commonly used as a model for Leishmania infection and has been
described as a suitable model for drug screening [24,25]. In vitro
infection of macrophages by Leishmania and analysis of intracellular
parasite growth requires a method allowing for robust detection,
discrimination and counting of parasites and host cells. In our
setting, THP-1 cells infected with L. donovani were stained with the
DNA marker DAPI (49,69-diamidino-2-phenylindole) allowing the
visualization of host cell nuclei and parasite kinetoplasts. Images
collected with an INCell Analyzer 1000 fluorescent microscope
showed a significant size difference between host cell nuclei and
parasite kinetoplasts. This feature was exploited for image
segmentation and determination of the number of host cells and
parasites (Figure 1A–D). The ratio between total number of
parasites and total number of host cells was calculated for each
well. In addition, counts of host cell nuclei were used as a
quantitative measure of cell toxicity induced by the compounds.
Incubation of L. donovani with THP-1 for 4 hours at a ratio of 15
parasites per host cell led to an average infection of 4.1 +/2 0.32
parasites per host cell after 72 h incubation, with an average of 30
+/2 9 percent of the cells infected and no change in the number
of host cells (Figure 1E). Growth of parasite and host cells was not
affected by 1% DMSO (Figure 2A–B). Amphotericin B, the first
line drug used against leishmaniasis, was used as a positive control.
At 2 mM amphotericin B did not affect THP-1 host macrophages
(Figure 2A) but significantly inhibited growth of intracellular L.
donovani (Figure 2B) with an estimated GI50 of 0.08 mM (Figure 2C).
This is comparable to GI50 values from previous reports [11,20].
Screening of a bioactive small molecule library against L.
donovani intracellular amastigotes and free living
promastigotes
The intracellular amastigote imaging assay described above was
used to screen a library of 909 bioactive small molecules (Iconix
library). In the primary screen, compounds were assayed in
duplicates at 10 mM. The average Z’ value calculated per plate
based on the positive and negative controls was 0.63, indicating a
satisfactory robustness of the assay. Sixty percent parasite growth
inhibition in at least one of the replicates was the cut-off arbitrarily
determined for hit selection. This low threshold was purposely
selected to evaluate sensitivity of the assay and guarantee
identification of all active compounds. In addition, compounds
toxic to the host cell, determined as inducing more than 20%
reduction in THP-1 numbers, were excluded. A total of 27
compounds met these criteria and were selected for further
analysis. This list of active chemicals included previously identified
anti-leishmanials such as amphotericin B, pentamidine isothionate
and tamoxifen citrate, thus validating the ability of the screen to
identify molecules active against Leishmania.
The Iconix library was screened in parallel against L. donovani
free-living promastigotes. Promastigote viability was determined
after 72 hours incubation with the compounds, using an ATP-
bioluminescence assay previously described for high-throughput
screening against Trypanosoma brucei [26]. This assay measures
luminescence produced by luciferase in presence of cellular ATP;
the intensity of light is proportional to the amount of ATP released
and correlates with the number of viable parasites (data not shown)
[27]. Amphotericin B at 2 mM was used as a positive control and
1% DMSO as a negative control. In the primary screen,
compounds were assayed at 10 mM. The assay was robust with
an average Z’ value of 0.72. Consistent with the image-based assay
targeting intracellular L. donovani, 60% parasite growth inhibition
was the cut-off used for active compound selection. Fifty-nine
compounds were selected as hits for further validation.
The comparison of the results obtained for these screens showed
that out of the 27 hits identified in the amastigote screen, 26 were
also present in the promastigote screen. Only one compound,
naloxonazine, showed complete specificity for the intracellular
amastigote stage. Out of the 59 compounds identified in the
promastigote screen, 19 were considered toxic to the THP-1
macrophage (Figure 3 and Table 1).
GI50 values for these 60 hits (59 identified in the promastigote
screen and one intracellular amastigote-specific hit) were then
Screen against Leishmania Intracellular Amastigote
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the hits) were equipotent against both stages of the parasite. 14
compounds (23%) were more potent against the intracellular
amastigotes while 13 compounds (22%) were more active against
the promastigotes. The remaining compounds were toxic to the
host cell (Table 1).
Figure 1. Infection of THP-1 with L. donovani: detection, segmentation and growth of host cell and parasite. A–D. Detection and
segmentation of THP-1 host cell and L. donovani intracellular amastigotes. Images obtained with the INCell Analyzer 1000 (20X) of THP-1 cells infected
with L. donovani and treated with 1% DMSO (A, B) or 2 mM amphotericin B (C, D). Insert shows the relative fluorescence of DAPI-stained parasite
kinetoplast (k) and nucleic DNA (n) and host cell nucleus (N). Segmentation of host cell nuclei and parasite kinetoplast using INCell developer toolbox
software (B, D). Red outline: parasite kinetoplast, blue outlines: host cell nucleus and border representing the boundary of the host cell. E. Evolution of
the number of parasites and THP-1 host cells in a 72 h time course. THP-1 and L. donovani were counted at several time points after infection using
the INCell 1000. White squares: average number of host nuclei per well (n=8); black circles: average number of parasites counted per well divided by
the total number of host nuclei per well (n=8).
doi:10.1371/journal.pntd.0001253.g001
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intracellular stage of the parasite, we analyzed their sensitivity to
the 60 hits described above. This study indicated that compound
activity against axenic amastigotes mostly correlated with
promastigotes. The specific activity of naloxonazine against
intracellular amastigotes was confirmed as this compound showed
no activity against promastigotes or axenic amastigotes (Table 1).
Differential activity of naloxone and naloxonazine, two
m-opioid receptor antagonists, against L. donovani
The Iconix collection contained two opioid receptor antago-
nists, naloxone and naloxonazine. The first was not selected as a
hit in any of the screens described above while the latter showed
specific activity against the intracellular amastigote stage. To
confirm these primary observations, the activity of both com-
pounds was tested against promastigotes, intracellular and axenic
amastigotes. Naloxonazine exhibited specific activity against
intracellular amastigotes (GI50 intracellular amastigote: 3.45 mM;
GI50 THP-1: 33.8 mM; GI50 promastigote: .50 mM; GI50 axenic
amastigote: .50 mM), while naloxone was inactive against all
parasite forms and not toxic to the host macrophage (Figure 4). At
a curative concentration, the selectivity window of naloxonazine
was reduced (GI90 intracellular amastigote: 12.5 mM; GI90 THP-1:
50 mM), limiting the possibility of using naloxonazine for
treatment.
Discussion
Current chemotherapy for Leishmaniasis has several draw-
backs, including cost, toxicities, route of administration, and the
emergence of drug resistance. The pipeline for anti-leishmanial
drugs therefore needs to be filled with new compounds. As the
discovery of new and original leads suitable for optimization and
drug development is dependent on the ability to screen many
compounds, assays should be rapid, inexpensive and reproducible
[14]. In addition, for pathogens displaying several life stages like
Leishmania, there is a need to determine the best parasite stage to
target. In the case of Leishmania there are three major options: first,
Figure 2. Treatment of infected THP-1 with DMSO and amphotericin B. A. Number of infected THP-1 counted per well treated or not with
1% DMSO or 2 mM amphotericin B. B. Number of parasites counted per well divided by the number of host nuclei per field. C. Dose response curve
for amphotericin B plotting the percentage of parasite growth inhibition. Values are mean from at least 3 independent experiments.
doi:10.1371/journal.pntd.0001253.g002
Figure 3. Number of hits identified with the intracellular
amastigote and the promastigote primary screens. White bar:
number of compounds identified in both screens. Light grey and black
bars: number of compounds specifically active against promastigotes
and intracellular amastigotes respectively. Hatched bar: number of
compounds active against the promastigote stage but determined as
toxic against THP-1 host cell in the intracellular amastigote screen.
doi:10.1371/journal.pntd.0001253.g003
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amastigotes.
Compounds
GI50 THP-1
(mM)
GI50 Intracellular
amastigote (mM)
GI50 Promastigote
(mM)
GI50 Axenic
amastigote (mM) Selectivity
a Specificity
b
Naloxonazine 33.8 3.49 .50 .50 9.68 14.32
Metergoline 37.14 0.78 15.08 .50 47.22 19.17
R(-)-Apomorphine .16.5 2.7 38.15 5.20 6.1 14.12
Clotrimazole .16.5 1.08 12.92 4.56 15.32 11.92
Cetylpyridinium chloride 9.16 0.41 3.30 0.92 22.34 8.05
Aminacrine 12.97 1.9 8.96 .16.5 6.82 4.71
4,49-Diethylaminoethoxyhexestrol 6.11 1.4 5 10.93 4.36 3.57
Hexachlorophene 16.5 4.54 15.88 14.76 3.62 3.49
Loperamide Hydrochloride .16.5 5.4 17.3 .50 3.02 3.15
Tamsulosin 27.97 6.3 20 .50 4.43 3.17
Salinomycin 16.09 0.92 2.71 0.06 17.30 2.92
Cycloheximide 21 1.15 2.95 0.39 18.13 2.55
Prazocin Hydrochloride 23.32 6.73 16.74 .50 3.46 2.48
Carvedilol 37.5 6.16 12.41 .16.5 6.07 2.01
Brilliant green 1.64 6 0.10 0.03 15.88 0.02
Antimycin A .50 2.15 0.1 0.01 500 0.05
BAY 11–7085 .50 .16,5 1.54 0.42 32.46 0.06
Haloprogin 20 6 1.05 0.56 19.04 0.17
Pentamidine Isethionate .50 9.55 1.69 1.64 29.49 0.17
Zinc Dibutyldithiocarbamate .50 .50 8.48 .50 5.89 0.17
Amlodipine .16.5 9.78 3.11 27 5.34 0.31
Nisoldipine .16,5 32.17 9.85 13.86 1.67 0.30
Parthenolide .16.5 .50 15.54 4.35 1.06 0.31
Pyrithione zinc 1.043 ND 0.07 0.01 14.9 ND
Thimerosal 12.81 ND 0.49 1.50 26.18 ND
Gramicidin 8.38 ND 0.68 5.76 12.19 ND
Digitonin 13.46 ND 4.376 13.81 3.075 ND
Emetine 1.28 0.082 0.03 1.62 15.58 0.42
Amphotericin B .50 1.12 1.61 5.42 44.52 1.43
Chlorhexidine .16,5 1.79 2.81 4.78 9.27 1.56
Oxiconazole .16,5 6.6 2.65 0.53 2.51 0.40
Bazedoxifene .16,5 4.8 6.52 .16.5 3.45 1.35
chlorquinaldol 39.3 5.5 6.3 1.72 7.14 1.14
Doxazocin .16,5 5 8.45 .16.5 3.32 1.69
Aclacynomycine a1 29.1 5.81 9.15 .16.5 5 1.57
Mebeverine .50 8.5 6.91 2.36 5.88 0.81
Miconazole .16,5 15.44 7.48 4.73 1.07 0.48
Terfenadine 39.03 14.4 11.92 0.61 2.71 0.82
Tamoxifen Citrate .16.5 20.79 10.22 .50 1.61 0.49
Auranofin 20.89 21.76 11.11 .50 1.88 0.51
Benzetonium chloride 40.18 10 11.34 10.7 3.54 1.13
Ciclopirox 42 22 15.25 .50 1.90 0.69
Sporidesmin A 0.02 ND 1.18 1.66 0.02 ND
Harringtonin 0.10 4.89 16.61 10.6 0.02 3.39
Screen against Leishmania Intracellular Amastigote
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axenic amastigote and third the intracellular amastigote stage. The
first and second options meet the reproducibility, rapidity and low
cost requirements for high-throughput screens, due to the ease in
manipulating promastigotes or axenic amastigotes in vitro. This has
been demonstrated by Siqueira-Neto et al. and Sharlow et al. who
described screening 26,500 and 200,000 compounds against the
Leishmania promastigote stage, respectively [11,12]. These assays
monitored parasite viability by measuring products from meta-
bolically active cells (The Alamar Blue assay involves reduction of
resazurin into fluorescent resorufin by live cells, while CellTiter-
Glo luciferase catalyzes the production of luminescence in the
presence of cellular ATP). The axenic amastigotes offer the ability
to screen easily the relevant-like stage of the parasite and allow
testing the potency of compounds under low pH conditions.
However, the major disadvantage of these two approaches is the
absence of the host cell in the assays: the natural niche of the
parasite is not taken into account and aspects of parasite biology
such as host-parasite interactions or accessibility of the target are
ignored.
The intracellular amastigote stage has been logically designated
as the more relevant target for primary screening against
Leishmania, but previous methods were labor intensive and would
not support automation [19,28]. Methods traditionally used to
Figure 4. Structure and activity of naloxonazine and naloxone. Lower panels: Dose response curve for naloxonazine (left) and naloxone
(right) against intracellular amastigotes (black diamonds), promastigotes (black squares), axenic amastigotes (white diamonds) and THP-1 (white
triangles) plotting the percentage of parasite growth inhibition.
doi:10.1371/journal.pntd.0001253.g004
Compounds
GI50 THP-1
(mM)
GI50 Intracellular
amastigote (mM)
GI50 Promastigote
(mM)
GI50 Axenic
amastigote (mM) Selectivity
a Specificity
b
3,39,49,5-tetrachlorosalicylanilide 0.32 ND 1.45 1.38 0.22 ND
Thiram 1.58 10.4 4.62 5.42 0.34 0.44
Idarubicin 1.89 ND 4.65 1.78 0.40 ND
Cerivastatin 7.15 .50 10.8 0.02 0.66 0.22
aSelectivity is the ratio between parasite GI50 and THP-1 GI50.
bSpecificity is the ratio between promastigote GI50 and intracellular amastigote GI50. Specificity value .2 was the cut-off chosen to define a compound as more active
against the intracellular amastigote stage; while a specificity value ,0.4 indicated a compound more active against promastigotes; compounds with specificity values
between 0.4 and 2 were considered active against both stages.
doi:10.1371/journal.pntd.0001253.t001
Table 1. Cont.
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Giemsa staining or the use of reporter gene-expressing parasites
(green fluorescent protein, luciferase or beta-galactosidase) [29,30].
Giemsa staining is cumbersome as it needs manual counting.
Reporter gene-expressing parasites are a powerful alternative, but
stable recombinant parasite populations are required and they do
not allow concomitant analysis of the host cell.
Here we describe a high content assay that allows the
simultaneous visualization of both host cell nuclei and parasite
kinetoplasts by using the DNA marker DAPI. The significant
difference in the size of these two organelles facilitates discrimi-
nation between host cells and parasites, and thus accurate
counting of both entities. Reduction in the number of kinetoplasts
gives a measure of inhibition of parasite growth, while a reduction
in the number of host cell nuclei is indicative of compound
cytotoxicity. Thus, this image-based assay allows the identification
of leishmaniocidal as well as leishmaniostatic compounds. All steps
of this assay are amenable to automation and could be reduced to
384-well format resulting in a robust high-throughput screening
methodology.
To evaluate what differences might be obtained from screening
against the extracellular versus the intracellular parasite stages, we
screened the same set of 909 compounds against both L. donovani
promastigotes and intracellular amastigotes. We observed that the
majority of the hits identified with the intracellular amastigote
screen, defined as inducing 60% parasite growth inhibition at
10 mM, were also found in the promastigote screen. One
compound showed specific inhibition of intracellular amastigote
and was completely inactive against promastigotes. Fifty-six
percent of the hits from the promastigote screen were not found
in the intracellular amastigote screen. These results indicated that
a promastigote screen failed to identify all active compounds and
led to 56% of compounds being likely false positives. Thus, while
the promastigote stage appears suitable for high-throughput
screening, a fraction of the hits would be missed; furthermore, a
high rate of false positives is characteristic of primary screens
against promastigotes, underlying the importance of evaluating
compound activity against intracellular amastigotes at least in a
secondary screen. This is in accordance with the findings of
Siqueira-Neto et al. who found that only 4% of their hits identified
in a promastigote primary screen were active in an intracellular
context [11]. Advantages of the intracellular amastigote assay
include cell-health information, very low cost of consumables and
a reduced necessity for secondary assays. The importance of the
host cell in the assay was also demonstrated by the dose response
study against axenic amastigotes (i.e. amastigote-like stage obtained
from differentiation of promastigotes in vitro in the absence of a
host cell); although this parasite form should mimic the
intracellular stage, the activity of compounds against axenic
amastigotes mostly correlated with promastigotes rather than
intracellular amastigotes.
A similar assay was also successfully developed for screening
drugs against the intracellular stage of the related parasite
Trypanosoma cruzi [31]. Screening the Iconix library against
intracellular T. cruzi identified 56 hits, among which 8 were also
hits in the Leishmania screen presented here. Six of these were
found to be more active against the intracellular amastigote stage
of L. donovani compared to promastigotes, indicating inter-species
activity of compounds only for the intracellular stages of these two
different parasites.
Fifty percent of the compounds that were preferentially active
against intracellular amastigotes are known to bind mammalian/
eukaryotic G protein coupled receptors (opioid receptors,
serotonin or dopamine receptors and adrenergic receptors).
Heterotrimeric G proteins are absent in trypanosomatids [32]
and we could not find convincing homologs of opioid receptors in
the Leishmania genome. Compounds described as ligands of G
protein coupled receptors may have different targets among
parasitic proteins, leading to mechanisms of inhibition indepen-
dent of the host cell. This is the case of a serotonin receptor
agonist that interferes with P. falciparum growth by blocking a
surface membrane channel [33], or a k-opioid agonist active
against T. brucei whose target remains to be identified as no
homolog of k-opioid receptor is found in the T. brucei genome
[34]. However, the fact that the ligands of G protein coupled
receptors identified in this study, showed a preferential activity
towards the intracellular amastigote stage, also highlights the
potential value of these host cell signaling pathways as targets.
Previous reports demonstrated the involvement of such receptors
in inhibition of infection by several intracellular pathogens
including Leishmania [35-37]. Targeting host factors essential for
parasite development is an emerging drug discovery paradigm. It
is assumed to be less likely to induce drug resistant pathogens and
offers the possibility to repurpose drugs by exploiting compounds
currently used for diseases unrelated to microbial infection
[38,39].
Interestingly, one compound out of 909 was active against the
intracellular amastigote stage but was completely inactive against
promastigotes. This compound, naloxonazine, was also inactive
against axenic amastigotes, indicating that its activity is dependent
on a macrophage function. Naloxonazine is described as an
irreversible m1-opioid receptor antagonist [40]. There is evidence
for the presence of opioid receptors on cells of the immune system
[41,42] and it is known that opioids are involved in modulation of
host resistance to infectious diseases [43,44]. The immune
response of mice infected with L. donovani has been shown to be
influenced by the opioid receptor agonist morphine, but the
receptors involved and the mechanism leading to this immuno-
modulation remain unknown [45]. Loperamide, a m-opioid
receptor agonist, was also identified in this study as inhibiting
parasite growth, and this compound was also more potent against
the intracellular stage of the parasite. Another m-opioid receptor
antagonist, naloxone, also present in the Iconix library, did not
show any activity against L. donovani. The differential selectivity of
naloxone and naloxonazine for opioid receptor binding sites might
explain their differential activity against intracellular L. donovani
[46]. Naloxone is monomer-like while naloxonazine appears as an
inverted dimer (Figure 4). The presence of the macrophage
appears to be essential for the activity of naloxonazine against L.
donovani, but the underlying cellular and molecular mechanisms
remain to be elucidated. Although naloxonazine itself would not
meet the requirement for a therapeutic drug due to the reduced
selectivity window at a curative concentration, it would be
interesting to analyze other compounds that target the same host
cell pathway.
In summary, we report an automated screen against intracel-
lular amastigotes of L. donovani. It has the advantage of screening
against the relevant stage of the parasite, taking into consideration
crucial aspects of its biology, and giving the opportunity to identify
host factors critical for the establishment of infection. This is
essential for the identification of new, original and diverse lead
compounds for anti-leishmanial therapy.
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